A New Higher-Strength Weight-Loss Injection Is Coming to the UK: What You Need to Know

The next evolution in medical weight loss is almost here. Novo Nordisk's Wegovy 7.2 mg - a higher-dose version of semaglutide - is expected to launch in the UK by late 2025 or early 2026.

Here's what you need to know about when it's coming, what studies show, who it could benefit, and how it compares with Mounjaro (tirzepatide).

What Is Wegovy 7.2 mg?

Wegovy is the brand name for semaglutide, a GLP-1 receptor agonist that helps regulate appetite and blood sugar levels.

• Currently, the 2.4 mg dose is approved in the UK for adults with obesity or weight-related conditions.
• The upcoming 7.2 mg dose is intended for patients who:
  • Have already used Wegovy 2.4 mg successfully,
  • Are tolerating it well, but
  • Have plateaued in their weight-loss journey and may benefit from a higher dose.

When Will Wegovy 7.2 mg Be Available in the UK?

According to Novo Nordisk and early market reports, Wegovy 7.2 mg is under review by European and UK regulators.

A UK launch window of late 2025 – early 2026 is expected, beginning with private prescriptions before wider NHS availability.

When it becomes available, PriceMyMeds.co.uk will feature live price comparisons across licensed UK online pharmacies - helping you find the best deals quickly and safely.

What Do the Clinical Studies Say?

In the latest STEP UP clinical studies:

• Average weight loss reached ≈ 21% of total body weight.
• Around 1 in 3 participants lost ≥ 25% of their starting weight.
• The side-effect profile was similar to existing Wegovy doses (mainly nausea and mild digestive upset).

This suggests the 7.2 mg strength could help long-term users who've reached a plateau achieve further progress.

Who Might Benefit Most?

The new Wegovy 7.2 mg dose could benefit:

• Adults already using semaglutide 2.4 mg who've plateaued.
• Those who respond well to GLP-1 therapy and prefer staying on the same medication.
• Individuals aiming for further weight loss without switching to a dual-agonist treatment like Mounjaro.

⚠️ Always speak to a healthcare professional before adjusting or starting any prescription medication. PriceMyMeds provides price comparison only - not medical advice.

Wegovy 7.2 mg vs Mounjaro: Key Differences

Mechanism

• Wegovy 7.2 mg: GLP-1 receptor agonist
• Mounjaro: Dual GIP + GLP-1 receptor agonist

Average Weight Loss

• Wegovy 7.2 mg: ~21% in STEP UP studies
• Mounjaro: ~22–23% in SURMOUNT trials

Approval Status (UK)

• Wegovy 7.2 mg: Expected late 2025 / early 2026
• Mounjaro: Available now (privately and limited NHS)

Cardiovascular Data

• Wegovy 7.2 mg: Proven 26% CV event reduction
• Mounjaro: CV studies ongoing

Side-Effects

• Wegovy 7.2 mg: Nausea, reflux, constipation
• Mounjaro: Nausea, diarrhoea, fatigue

Frequency

• Wegovy 7.2 mg: Weekly injection
• Mounjaro: Weekly injection

Both medications are once-weekly injections for chronic weight management, but Mounjaro's dual mechanism may offer slightly higher average results.

However, Wegovy 7.2 mg could narrow that gap for current semaglutide users.

Comparing Prices: Wegovy 7.2 mg vs Mounjaro

Pricing for Wegovy 7.2 mg has not yet been confirmed.

However, early indicators suggest semaglutide formulations may remain slightly more affordable than Mounjaro in UK private clinics.

When launched, PriceMyMeds will show:

• Verified online pharmacy prices for Wegovy and Mounjaro
• Cost comparisons across different strengths and pack sizes
• Direct links to trusted, MHRA-approved providers

That means no guesswork, no spam sites - just clear, verified prices.

Summary: Wegovy 7.2 mg in the UK

• Expected UK launch: Late 2025 – early 2026
• Average weight loss: ≈ 21% in trials
• Designed for: Existing Wegovy users needing additional progress
• Comparison: Efficacy approaching Mounjaro, with known safety profile
• Next step: Compare pharmacy prices when it becomes available on PriceMyMeds.co.uk

Stay Updated

Sign up at PriceMyMeds.co.uk to get notified when Wegovy 7.2 mg hits UK pharmacies - and be the first to compare real-time prices from verified providers.